Similar articles

• Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty.

  George MD, Baker JF, Winthrop K, Curtis JR. George MD, et al. Ann Intern Med. 2019 Nov 5;171(9):680. doi: 10.7326/L19-0528. Ann Intern Med. 2019. PMID: 31683280 No abstract available.
• Risk of Biologics and Glucocorticoids in Patients With Rheumatoid Arthritis Undergoing Arthroplasty.

  Boers M. Boers M. Ann Intern Med. 2019 Nov 5;171(9):679-680. doi: 10.7326/L19-0527. Ann Intern Med. 2019. PMID: 31683279 No abstract available.
• Flares in Patients with Rheumatoid Arthritis after Total Hip and Total Knee Arthroplasty: Rates, Characteristics, and Risk Factors.

  Goodman SM, Bykerk VP, DiCarlo E, Cummings RW, Donlin LT, Orange DE, Hoang A, Mirza S, McNamara M, Andersen K, Bartlett SJ, Szymonifka J, Figgie MP. Goodman SM, et al. J Rheumatol. 2018 May;45(5):604-611. doi: 10.3899/jrheum.170366. Epub 2018 Mar 15. J Rheumatol. 2018. PMID: 29545451
• Rheumatoid arthritis: Perioperative management of biologics and DMARDs.

  Goodman SM. Goodman SM. Semin Arthritis Rheum. 2015 Jun;44(6):627-32. doi: 10.1016/j.semarthrit.2015.01.008. Epub 2015 Jan 30. Semin Arthritis Rheum. 2015. PMID: 25747348 Review.
• [Discontinuation or tapering strategies of biologics in rheumatoid arthritis in remission].

  Mallick A, Fautrel B, Sagez F, Sordet C, Javier RM, Petit H, Chatelus E, Rahal N, Gottenberg JE, Sibilia J. Mallick A, et al. Rev Med Interne. 2017 Apr;38(4):256-263. doi: 10.1016/j.revmed.2016.12.014. Epub 2017 Feb 1. Rev Med Interne. 2017. PMID: 28161110 Review. French.